ACHE Overview
Molecule Name
Acetylcholinesterase
Synonyms
acetylcholinesterase (Yt blood group),Acetylcholinesterase,ACHE,apoptosis-related acetylcholinesterase,ARACHE,EC 3.1.1,EC 3.1.1.7,N-ACHE,Yt blood group,YT
Drug Development Progress
Drugs in Clinical Trials31
Approved Drugs27
Highest Development StageApproved
Target Synonym
EC:3.1.1.7，EC 3.1.1，Acetylcholinesterase (YT Blood Group)，Acetylcholinesterase (Cartwright Blood Group)，Yt Blood Group，Apoptosis-Related Acetylcholinesterase，Acetylcholinesterase，EC 3.1.1.7，ARACHE，N-ACHE，ACEE，AChE，YT
Background
The enzyme acetylcholinesterase, also known as AChE or acetylhydrolase, is the primary cholinesterase in the body. It is a serine hydrolase whose primary function is to catalyzes the breakdown of acetylcholine(ACh) and of some other choline esters that function as neurotransmitters. AChE is found at mainly neuromuscular junctions and in chemical synapses of the cholinergic type, where its activity serves to terminate synaptic transmission. Acetylcholine deficit has been found in Alzheimer's disease (AD) ans is associated with cognetive decline. Therefore, AChE has been reported to be a viable therapeutic target for the treatment of AD and other dementias. To this end, acetylcholinesterase inhibitors (AChEIs) are commonly used.
ACHE Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Donepezil/Solifenacin | CPC-201 | Phase 3 Clinical | Allergan Plc, Cipla Inc | Alzheimer Disease; Dementia; Urologic Diseases | Details |
| Botulinum toxin (CKD Bio) | CKDB-501B; CKDB-501-B; CKDB-501A; CKDB-501-A; CKDB-501 | Phase 3 Clinical | CKD Bio Corp | Glabellar lines; Spasm | Details |
| BR-4001 | BNT-002; BR-4001 | Phase 3 Clinical | Boryung Pharmaceutical Co Ltd | Alzheimer Disease | Details |
| Blarcamesine/Donepezil Hydrochloride | Phase 2 Clinical | Anavex Life Sciences Corp | Alzheimer Disease | Details | |
| Pregnenolone | NBI-113 | Phase 2 Clinical | Neurocrine Biosciences Inc | Alcoholism; Anxiety; Autism Spectrum Disorder; Autistic Disorder; Cocaine-Related Disorders; Depression; Depressive Disorder, Major; Low Back Pain; Menopausal symptoms; Schizophrenia; Stress Disorders, Post-Traumatic | Details |
| Fluoropezil | DC-20; DC-511020 | Phase 2 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Alzheimer Disease | Details |
| Pyridostigmine extended release (Kashiv BioSciences) | K-127 | Phase 2 Clinical | Kashiv BioSciences LLC | Blepharoptosis; Fatigue Syndrome, Chronic; Musculoskeletal Diseases; Myasthenia Gravis; Post-Acute COVID-19 Syndrome; Urination Disorders | Details |
| Donepezil long-acting Injection (Inventage Lab) | IVL-3003 | Phase 2 Clinical | Inventage Lab Inc | Alzheimer Disease | Details |
| YY-003 | YY003; YY-003 | Phase 2 Clinical | Chongqing Claruvis Pharmaceutical Co Ltd | Glabellar lines | Details |
| AT-004(Arctic Therapeutics) | AT-004(Arctic Therapeutics) | Phase 2 Clinical | Arctic Therapeutics International | Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea | Details |
| Galantamine/Metformin | RJx-01 | Phase 2 Clinical | Rejuvenate Biomed NV | Muscle Weakness; Muscular Atrophy; Sarcopenia | Details |
| Huperizine-A (Biscayne Pharmaceuticals) | BIS-001; INS-001; XEL-001-HP; SPN-817; BIS-001-ER; XEL-001-HG; Hup-A | Phase 2 Clinical | Harvard University | Epilepsy, Complex Partial; Seizures | Details |
| EX-039 | EX-039 | Phase 2 Clinical | Excelsior Corp | Alzheimer Disease | Details |
| donepezil (Vyant Bio) | VYNT-0126 | Phase 2 Clinical | Vyant Bio Inc | Rett Syndrome | Details |
| YIV-906 | PHY-906; KD-018 | Phase 2 Clinical | Phytoceutica Inc | Carcinoma, Hepatocellular; Colorectal Neoplasms; Diarrhea; Hepatitis B; Liver Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
| Edrophonium Chloride | Phase 1 Clinical | Teligent | Myasthenia Gravis | Details | |
| 18F-flubatine | Fluorine-18-flubatine; flubatine-[18F]; 18F-flubatine; norchloro-fluoroepibatidine-[18F] | Phase 1 Clinical | Helmholtz-Zentrum Dresden-Rossendorf | Alzheimer Disease | Details |
| Phenserine tartrate | DWJ301 | Phase 1 Clinical | Qr Pharma | Alzheimer Disease; Cognitive Dysfunction | Details |
| Mecripyrine Hydrochloride | SCR-1693; Y-1A; Y-1 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, NeuroDawn Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd | Alzheimer Disease; Brain Neoplasms | Details |
| Methanesulfonyl fluoride | SNX-001 | Phase 1 Clinical | Senexta | Alzheimer Disease | Details |
| NB-02 | NB-02; DA-9803 | Phase 1 Clinical | Dong-A ST Co Ltd | Alzheimer Disease; Lymphoma, Non-Hodgkin | Details |
| NDC-011 | NDC-011 | Phase 1 Clinical | Dr. Noah Biotech Inc | Amyotrophic Lateral Sclerosis | Details |
| Donepel hydrochloride oral instant membrane(Sichuan Baili Pharma) | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Alzheimer Disease | Details | |
| Donepezil Hydrochloride Oral Soluble Film(Shanxi Hcxf Pharma) | Phase 1 Clinical | Shanxi Hcxf Pharmaceutical Co Ltd | Alzheimer Disease | Details | |
| Donepezil Hydrochloride Oral Soluble Film(Hangzhou Heze Pharma) | HZ007; HZ-007 | Phase 1 Clinical | Hangzhou Heze Pharmaceutical Technology Co Ltd | Alzheimer Disease; Dementia | Details |
| Huperzine A Oral Solution(Universal Pharmaceutical Group) | Phase 1 Clinical | Universal Pharmaceutical Group Co Ltd | Myasthenia Gravis | Details | |
| Donepezil transdermal patch（Dong-A ST） | DA-5207 | Phase 1 Clinical | Dong-A ST Co Ltd | Details | |
| HHT-201 | HHT-201 | Phase 1 Clinical | Zhejiang Huahai Pharmaceutical Co Ltd | Alzheimer Disease; Hypertension | Details |
| Rivastigmine (Lachesis Biosciences Pty) | Clinical | Lachesis Biosciences Pty Ltd | Nerve Degeneration | Details | |
| donepezil (Daewoong) | DWJ-1365 | Clinical | Daewoong Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Galantamine Hydrobromide | GP-37267; R-113675 | Approved | AverTox, Nivalin, Reminyl, Razadyne, Reminyl XL | Mainland China | Alzheimer Disease | null | 1981-01-01 | AIDS Dementia Complex; Alzheimer Disease; Autistic Disorder; Bipolar Disorder; Brain Diseases; Cocaine-Related Disorders; Cognition Disorders; Dementia; Dementia, Vascular; Depressive Disorder, Major; Fasting; Frontotemporal Dementia; Insulin Resistance; Lewy Body Disease; Memory; Mental Disorders; Nervous System Diseases; Obesity; Schizophrenia; Stroke; Subarachnoid Hemorrhage; Tobacco Use Disorder; Vascular Diseases | Details | |
| Neostigmine Bromide | Approved | Prostigmin | Mainland China | Flatulence; Urinary Retention; Myasthenia Gravis | Shanghai Sine Pharmaceutical Laboratories Co Ltd | 1995-01-01 | Delayed Emergence from Anesthesia; Flatulence; Headache; Hypertension; Hyperventilation; Hypoxia; Myasthenia Gravis; Tachycardia; Urinary Retention | Details | ||
| Metrifonate | Bay-a-9826; Bayer-L-1359 | Approved | ProMem, Memobay, Bilarcil | Schistosomiasis | Details | |||||
| Rivastigmine Tartrate | SDZ-212-713; SDZ 212713; SDZ-ENA-713; ONO-2540; ENA-713; ENA-713D | Approved | Novartis Pharma Ag | Exelon TDS, Rivastach, Exelon MR, Prometax, Exelon, 艾斯能 | EU | Alzheimer Disease; Parkinson Disease; Dementia | Novartis Europharm Ltd | 1998-05-11 | Alzheimer Disease; Anticholinergic Syndrome; Brain Injuries, Traumatic; Cocaine-Related Disorders; Cognition Disorders; Delirium; Dementia; Dementia, Vascular; Down Syndrome; Neurobehavioral Manifestations; Parkinson Disease; Substance-Related Disorders | Details |
| Pyridostigmine Bromide | Ro-1-5130 | Approved | Valeant | Regonol, Mestinon | United States | Lambert-Eaton Myasthenic Syndrome | Bausch & Lomb (Singapore) Pvi Ltd | 1955-04-06 | Colonic Diseases; Constipation; Coronavirus Disease 2019 (COVID-19); Diabetes Mellitus; Dyskinesias; Fatigue Syndrome, Chronic; Fibromyalgia; Glycogen Storage Disease Type II; Heart Failure; HIV Infections; Hypotension, Orthostatic; Immunologic Deficiency Syndromes; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Parkinson Disease; Poisoning; Postural Orthostatic Tachycardia Syndrome; Primary Dysautonomias; Scleroderma, Systemic; T-Lymphocytopenia, Idiopathic CD4-Positive | Details |
| Dimebolin hydrochloride | BRN-0622478; PF-01913539; DMB-I | Approved | Bigespas Ltd | Dimebon | Russian Federation | Hypersensitivity; Rhinitis, Allergic; Dermatitis, Atopic | null | 1983-01-01 | Alzheimer Disease; Dementia; Dermatitis, Atopic; Huntington Disease; Hypersensitivity; Liver Failure; Rhinitis, Allergic | Details |
| Donepezil Hydrochloride | DKF-310; BNAG; E-2020; E-2022; (±)-E-2020; IVL-3003; GB-5001 | Approved | Eisai Co Ltd | Memac, Eranz, Memorit, Aricept Evess, Aricept, Aricept ODT, Aricept D, 安理申, ADLARITY | United States | Alzheimer Disease | Eisai Inc | 1996-11-25 | Alcoholism; Alzheimer Disease; Anorexia Nervosa; Anxiety Disorders; Aphasia; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Autistic Disorder; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; CNS Embryonal Tumor; Cognition Disorders; Cognitive Dysfunction; Delirium; Dementia; Dementia, Vascular; Depression; Diabetes Mellitus, Type 2; Down Syndrome; Fatigue; Fragile X Syndrome; Hearing Loss, Sensorineural; Ischemic Stroke; Lewy Body Disease; Memory Disorders; Migraine Disorders; Multiple Sclerosis; Neoplasms; Neurologic Manifestations; Neurotoxicity Syndromes; Osteoporosis; Parkinson Disease; Psychological Distress; Sleep Wake Disorders; Stroke; Subarachnoid Hemorrhage; Supranuclear Palsy, Progressive; Wounds and Injuries | Details |
| Memantine Hydrochloride/Donepezil Hydrochloride | ADS-8704; D-797/D-324; CKD 355; BPS-034; BPDO-1603; MDX-8704 | Approved | Allergan Plc | Arimenda, Namzaric | United States | Alzheimer Disease | Abbvie Inc | 2014-12-23 | Alzheimer Disease | Details |
| Huperzine A | SPN-817 | Approved | Chinese Academy Of Sciences, Mayo Clinic | 哈伯因, 双益平 | Mainland China | Alzheimer Disease | Henan Taloph Pharmaceutical Stock Co Ltd | 1994-01-01 | Alzheimer Disease; Brain Injuries, Traumatic; Epilepsy; Learning Disabilities; Memory Disorders; Schizophrenia; Seizures | Details |
| Distigmine Bromide | BC-51 | Approved | Torii Pharmaceutical Co Ltd | Ubretid | Japan | Dysuria; Myasthenia Gravis | Torii Pharmaceutical Co Ltd | 1967-09-05 | Dysuria; Esotropia; Glaucoma; Myasthenia Gravis | Details |
| Pralidoxime Chloride | 2-PAM-chloride | Approved | Baxter International Inc | Protopam chloride | United States | Poisoning | Baxter Healthcare Corp | 1964-03-11 | Poisoning | Details |
| Pralidoxime Iodide | 2-PAMI; NSC-7760; 2-PAM Iodide | Approved | Japan | Poisoning | Sumitomo Dainippon | 1958-05-01 | Poisoning | Details | ||
| Eserine Salicylate | Approved | Synapton SR, Xalieve, Antilirium | Delirium; Glaucoma; Insulin Resistance; Pain, Postoperative; Psychotic Disorders | Details | ||||||
| Neostigmine methylsulfate | Approved | Bloxiverz, Intrastigmina, Juvastigmin, Stiglyn, Metastigmin | Japan | Myasthenia Gravis; Muscle Hypotonia | kyowayakuhin Co | 1936-10-01 | Flatulence; Muscle Hypotonia; Myasthenia Gravis; Neuromuscular Blockade; Urinary Retention | Details | ||
| Naphazoline Hydrochloride/Neostigmine methylsulfate/Glycyrrhizinate dipotassium/Chlorphenamine Maleate/Aspartic Acid/Vitamin B6 | Approved | 新乐敦 | Details | |||||||
| Dextrose/Sodium Chloride/Potassium Chloride/Floxacillin sodium | Approved | Details | ||||||||
| Dextrose/Sodium Chloride/Potassium Chloride/Anthralin | Approved | Details | ||||||||
| Dextrose/Sodium Chloride/Potassium Chloride/Pralidoxime Chloride | Approved | Details | ||||||||
| Pralidoxime Chloride/Benactyzine Hydrochloride/Atropine Sulfate | Approved | Poisoning | Details | |||||||
| Naphazoline Hydrochloride/Neostigmine methylsulfate | Approved | Details | ||||||||
| Dihydrogalanthamine Hydrobromide | Approved | Mainland China | Hemiplegia; Sciatica | null | 1982-01-01 | Hemiplegia; Sciatica | Details | |||
| Securinine Nitrate | Approved | Facial Paralysis; Poliomyelitis | Details | |||||||
| Rivastigmine Twice Weekly Transdermal Patch (Luye Pharma) | LY-03013; LY-30410; RID-TDS | Approved | Acino International AG | Rivirec, 金斯明, Kingsmin, Rivalif® | Mainland China | Alzheimer Disease | Luye Pharma Group Ltd | Alzheimer Disease; Parkinson Disease | Details | |
| Glycopyrronium bromide/Neostigmine metilsulfate | Approved | Sintetica Gmbh | Novistig, Prevduo | Austria | Neuromuscular Blockade | Sintetica Gmbh | 2020-09-23 | Neuromuscular Blockade | Details | |
| Benzgalantamine gluconate | GLN-1062; ALPHA-1062; ALPHA-1062IN; Alpha 1062; ALPHA-1062 Intranasal | Approved | Galantos Pharma GmbH | Zunveyl | United States | Alzheimer Disease | Alpha Cognition Inc | 2024-07-26 | Alzheimer Disease; Brain Injuries, Traumatic; Cognitive Dysfunction | Details |
| Atropine/Pralidoxime Chloride | Approved | Meridian Medical Technologies Inc | DUODOTE | United States | Poisoning; Organophosphate Poisoning | Meridian Medical Technologies LLC | 2002-01-17 | Drug intoxications; Drug-Related Side Effects and Adverse Reactions; Organophosphate Poisoning; Poisoning | Details | |
| Acotiamide Hydrochloride Hydrate | Z-338; YM-443 | Approved | Zeria | Acofide | Japan | Dyspepsia | null | 2013-03-25 | Dyspepsia; Nausea | Details |